MNG490
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.338
- IL6_JAK_STAT3_SIGNALING+0.292
- INTERFERON_GAMMA_RESPONSE+0.279
- INFLAMMATORY_RESPONSE+0.222
- APICAL_SURFACE+0.191
- COAGULATION+0.181
- KRAS_SIGNALING_DN+0.179
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.175
- MYOGENESIS+0.168
- INTERFERON_ALPHA_RESPONSE+0.135
Top 10 suppressed
- G2M_CHECKPOINT-0.442
- MTORC1_SIGNALING-0.438
- CHOLESTEROL_HOMEOSTASIS-0.434
- E2F_TARGETS-0.420
- MYC_TARGETS_V1-0.417
- UNFOLDED_PROTEIN_RESPONSE-0.326
- PROTEIN_SECRETION-0.321
- MYC_TARGETS_V2-0.297
- MITOTIC_SPINDLE-0.280
- GLYCOLYSIS-0.264
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG537 | — | — | 0.899 |
| 2 | MNG450 | — | — | 0.879 |
| 3 | SRR8518299 | — | A | 0.871 |
| 4 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.871 |
| 5 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.869 |
| 6 | SRR12202486 | — | — | 0.867 |
| 7 | TCGA-CV-A6K0-01B-21R-A31N-07 | — | — | 0.866 |
| 8 | MNG617 | — | — | 0.863 |
| 9 | SRR12202445 | — | — | 0.863 |
| 10 | SRR1797234 | — | cohortMD2 | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.338 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.292 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.279 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.222 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.191 | Temsirolimus | — uncovered |
| COAGULATION | 0.181 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.179 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.175 | Inavolisib | — uncovered |
| MYOGENESIS | 0.168 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.135 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.093 | Inavolisib | — uncovered |
| COMPLEMENT | 0.074 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.065 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.053 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.041 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.036 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.012 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.009 | Temsirolimus | — uncovered |